Printer Friendly

VERTEX PHARMACEUTICALS AND POLYGEN MOLECULAR SIMULATIONS SIGN STRATEGIC COLLABORATION AGREEMENT

 VERTEX PHARMACEUTICALS AND POLYGEN MOLECULAR SIMULATIONS
 SIGN STRATEGIC COLLABORATION AGREEMENT
 CAMBRIDGE, Mass., Jan. 30 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Polygen Molecular Simulations Inc. (NASDAQ: PMSI) announced today that they have signed an agreement to collaborate on the development of advanced software for use in structure-based rational drug design.
 "This agreement will enhance Vertex's drug design programs by ensuring that we have comprehensive access to the most advanced computational chemistry and molecular modeling software available," said Dr. Joshua Boger, president of Vertex. "In addition, this collaboration will allow us to play an important role in developing new software tools with Polygen Molecular Simulations, reducing our needs for in-house software development." Dr. Boger added that "PMSI's choice of Vertex as a partner recognizes the quality and depth of our scientific staff as well as our leading role in the practical application of diverse experimental and computational techniques to rational drug design."
 "This collaboration is the first of its kind," said Michael J. Savage, Polygen Molecular Simulations' president and CEO. "It will involve the application of PMSI molecular modeling technology throughout the drug discovery process. The benefits of this close collaboration are expected to be considerable in the simulation and management of molecular and structural information as part of the drug design process."
 Under the terms of the agreement, Vertex will have special access to Polygen Molecular Simulations' computational chemistry and molecular modeling software over a 10-year period. PMSI will also give Vertex access to early versions of PMSI software products. In return, Vertex will help PMSI to enhance its software in areas such as NMR, X-ray crystallography, protein structure determination and analysis, conformational analysis, chemical and biological databases, and novel small molecule drug design. As part of the agreement, Vertex will acquire a technology license from PMSI, and PMSI will receive certain rights of refusal on molecular modeling methods and software which Vertex chooses to commercialize.
 Polygen Molecular Simulations, founded in 1985, is a leading supplier of molecular modeling software products in the pharmaceutical, chemical and materials science marketplace. The company's computational chemistry sofware runs on platforms from Convex, Cray Research, Digital Equipment Corp., Evans & Sutherland, Hewlett-Packard Co., IBM, and Silicon Graphics. Headquartered in Waltham, Mass., the company has 130 employees worldwide.
 Vertex is a leader in the use of structure-based rational drug design, a scientific approach to drug discovery through which synthetic compounds are designed at the atomic level to interact with protein targets associated with particular disease processes. Vertex applies this approach, involving the integration of advanced biology, chemistry, and biophysics to create novel, small molecule compounds, with the goal of developing these compounds into orally deliverable drugs to treat major diseases. The company is focusing on three major therapeutic areas: immunology, antiviral chemotherapy, and inflammation. Vertex's goal is to become a fully integrated pharmaceutical firm by exploiting the advantages of rational drug design in the discovery and development of novel drugs.
 -0- 1/30/92
 /CONTACT: Rich Aldrich, vice president of Vertex, 617-576-3111; or Carolynn Sherby, director of Polygen Molecular Simulations, 408-522-9214/
 (VRTX PMSI) CO: Vertex Pharmaceuticals; Ploygen Molecular Simulations ST: Massachusetts IN: MTC SU:


EG-DD -- NE006 -- 5159 01/30/92 10:43 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 30, 1992
Words:527
Previous Article:MICHAEL O. MAGDOL ELECTED VICE CHAIRMAN OF FIDUCIARY TRUST INTERNATIONAL
Next Article:TEAM REPORTS DIVIDEND
Topics:


Related Articles
VERTEX AND KISSEI PHARMACEUTICAL SIGN $20 MILLION AGREEMENT TO DEVELOP NOVEL DRUGS TO TREAT HIV INFECTION AND AIDS
VERTEX AND ROUSSEL UCLAF SIGN $30 MILLION AGREEMENT TO DEVELOP NOVEL DRUGS TO TREAT INFLAMMATION
OXFORD MOLECULAR, UNIVERSITY OF CALIFORNIA SAN FRANCISCO FORM CO-DISTRIBUTION PARTNERSHIP FOR AMBER
KISSEI PHARMACEUTICAL CO. BEGINS CLINICAL TRIAL PROGRAM IN JAPAN WITH VERTEX PHARMACEUTICALS' HIV PROTEASE INHIBITOR
Oxford Molecular Group and PolyMASC Sign Drug Design Collaboration
Vertex and Eli Lilly Form Strategic Alliance to Develop Drugs to Treat Hepatitis C Infection
Vertex and Schering AG Form Strategic Alliance to Develop Drugs for Treatment of Neurological Diseases
AstraZeneca Implements Global License of Accelrys Modeling Software.
Accelrys Announces Global Licensing Agreement With Lilly; Top Life Sciences Simulation Software Package To Be Customized and Deployed to Speed Drug...
Vertex secures hepatitis C license agreement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters